CorVista Health Announces Drs. Vallerie V. McLaughlin and Mark G. Rabbat Join Medical Advisory Board

WASHINGTON--(BUSINESS WIRE)--CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the expansion of their Medical Advisory Board with the appointment of Drs. Vallerie V. McLaughlin and Mark G. Rabbat. The expansion of the Medical Advisory Board reflects the company’s focus on pulmonary hypertension, coronary artery disease and machine learning.

Vallerie V McLaughlin, MD, is the Kim A Eagle, MD Endowed Professor of Cardiovascular Medicine and Director of the Pulmonary Hypertension Program at the University of Michigan Medical School in Ann Arbor, Michigan. She has been the Principal Investigator of several major clinical trials of drug therapies for pulmonary arterial hypertension and has published numerous papers in this field. She is a section editor for JACC-Heart Failure, a Senior Guest Editor for Circulation, and past Editor-in-Chief of Advances in Pulmonary Hypertension. She is a past Chair of the Scientific Leadership Committee and the Board of Trustees of the Pulmonary Hypertension Association, has chaired the American College of Cardiology Foundation/AHA Clinical Expert Consensus Document Committee for Pulmonary Arterial Hypertension, and is a founding member of the World Symposium on Pulmonary Hypertension Association.

“We are thrilled to welcome Drs. McLaughlin and Rabbat to our Medical Advisory Board. Their expertise will be instrumental as we seek to bring the CorVista System to market,” said Don Crawford, CorVista Health chief executive officer. “Dr. McLaughlin’s passion for and expertise in pulmonary hypertension and Dr. Rabbat’s knowledge of the coronary artery disease, AI and imaging will help advance CorVista Health’s solution to aiding clinicians in diagnosing and treating cardiovascular disease.”

Mark Rabbat, M.D. is Associate Professor of Medicine and Radiology in the Division of Cardiology and Director, Cardiac CT. Dr. Rabbat completed his cardiovascular medicine and advanced cardiovascular imaging fellowships at Loyola University. Dr. Rabbat has published over 200 manuscripts, book chapters, editorials, reports, and abstracts. Dr. Rabbat's publications are referenced in the new United States American Heart Association and American College of Cardiology Guideline for the Evaluation and Diagnosis of Chest Pain. Dr. Rabbat received an investigator award and was awarded Scholar in Cardiovascular Disease and Stroke by the American Heart Association. He is the current chair-elect of the advocacy committee of the Society of Cardiovascular CT. He received a research fellow award through Alpha Omega Alpha (AOA) for his research at Brigham and Women’s Hospital, Harvard Medical School. Dr. Rabbat serves as course director for various advanced cardiac imaging courses and was asked to serve as Chairperson for a debate on Artificial Intelligence (AI) in Cardiology at the prestigious European Society of Cardiology Annual Congress.

To hear more from Dr. McLaughlin, listen to The Cor Podcast Episode 3: Pulmonary Hypertension - The Challenges and Shortcomings

About CorVista® System
CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.

About CorVista Health, Inc.
CorVista Health, Inc. is a subsidiary of Toronto-based Analytics For Life Inc. CorVista Health is applying machine learning using real world test data to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. For more information, visit www.corvista.com.